<?xml version="1.0" encoding="UTF-8"?>
<p>A number of adverse effects are associated with CD19-targeted CAR T-cell therapy. The 2 most common treatment-related toxic effects include cytokine release syndrome (CRS) and neurologic toxic effects. CRS, a potentially life-threatening condition mediated by the elevation of proinflammatory cytokines, including interleukin 6 (IL-6), coincides with CAR T-cell expansion and usually occurs during the first 3â€“4 weeks of CAR T-cell infusion (CTI) [
 <xref rid="CIT0003" ref-type="bibr">3</xref>, 
 <xref rid="CIT0004" ref-type="bibr">4</xref>].
</p>
